Fate Therapeutics
FATE
260 hedge funds and large institutions have $7.73B invested in Fate Therapeutics in 2021 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 90 increasing their positions, 90 reducing their positions, and 36 closing their positions.
44% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 36
5% more funds holding
Funds holding: 248 → 260 (+12)
0.42% more ownership
Funds ownership: 99.57% → 99.98% (+0.42%)
0% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 90
3% less capital invested
Capital invested by funds: $7.95B → $7.73B (-$218M)
10% less call options, than puts
Call options by funds: $23.3M | Put options by funds: $25.8M
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$350M |
| 2 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$82.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.8M |
| 5 |
BlackRock
New York
|
+$47.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$105M |
| 2 |
Janus Henderson Group
London,
|
-$61.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$40.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.7M |
| 5 |
GH
Grosvenor Holdings
Chicago,
Illinois
|
-$32.2M |
FATE Hedge Fund Activity: Q1 2021 in Review
260 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2021, worth a combined $7.73B — down 2.7% from $7.95B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new FATE positions and 36 closed out — a net gain of 16 holders — while 90 added to existing stakes and 90 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $350M. The largest seller was Farallon Capital Management, cutting an estimated $105M.
- 260 institutional investors held Fate Therapeutics (FATE) as of Q1 2021, up from 248 in Q4 2020.
- Funds reported $7.73B of Fate Therapeutics stock for Q1 2021, down 2.7% quarter-over-quarter.
- 52 funds opened new Fate Therapeutics positions in Q1 2021 and 36 closed out, a net change of +16 holders.
- The largest Fate Therapeutics buyer in Q1 2021 was ARK Investment Management, an estimated $350M added.
- The largest Fate Therapeutics seller in Q1 2021 was Farallon Capital Management, an estimated $105M sold.
Based on aggregated 13F filings for Q1 2021.